Clinical Trial Update: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating denifanstat for metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Denifanstat (denifanstat)

Snippet

Sponsor: Sagimet Biosciences Inc. | Conditions: MASH, NASH | Phase 3 | Status: WITHDRAWN